- Home
- ARHS vs INBX Comparison
ARHS vs INBX Comparison
Compare ARHS & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARHS | INBX |
|---|---|---|
| Founded | 1986 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 956.8M | 999.7M |
| IPO Year | 2021 | 2024 |
Fundamental Metrics
Financial Performance| Metric | ARHS | INBX |
|---|---|---|
| Price | $5.73 | $111.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 3 |
| Target Price | $10.78 | ★ $150.00 |
| AVG Volume (30 Days) | ★ 1.3M | 586.3K |
| Earning Date | 05-07-2026 | 05-15-2026 |
| Dividend Yield | ★ 4.78% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $1,379,222,000.00 | $1,300,000.00 |
| Revenue This Year | $7.23 | N/A |
| Revenue Next Year | $7.10 | N/A |
| P/E Ratio | $293.00 | ★ N/A |
| Revenue Growth | 8.51 | ★ 550.00 |
| 52 Week Low | $5.63 | $12.80 |
| 52 Week High | $12.97 | $155.29 |
Technical Indicators
Market Signals| Indicator | ARHS | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 29.88 | 50.41 |
| Support Level | N/A | $69.30 |
| Resistance Level | $7.62 | $155.29 |
| Average True Range (ATR) | 0.35 | 13.20 |
| MACD | -0.18 | -3.55 |
| Stochastic Oscillator | 3.25 | 23.22 |
Price Performance
Historical ComparisonAbout ARHS Arhaus Inc.
Arhaus Inc is a growing lifestyle brand and omnichannel retailer of premium home furniture. The company offers merchandise in several categories, including furniture, outdoor, lighting, textiles, and decor through its Retail and e-commerce sales channels.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.